MedTrace Logo

the Remineralizing Self-Assembling Peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride White Spot Lesions

NCT05127889 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-11-19

No results posted yet for this study

Summary

The aim of the current study is to compare the remineralizing ability of Self-assembling peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride varnishes in treatment of white spot lesions both in-vivo and in-vitro .

A) Primary Objective

Assessment of:

* Dimensions of the WSLs through digital photography.
* The color of WSLs through spectrophotometer. B) Secondary Objectives

Assessment of:

• Degree of remineralization using Polarized Light Microscope.

Conditions

  • Prevention of White Spot Lesions

Interventions

DRUG

curodont

* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide. * The varnish will be mixed with the brush to avoid separation of the material during storage * However, to guarantee the best results suction will be used during application of the varnish. * A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush * The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles. * After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-04-02
Completion
2024-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127889 on ClinicalTrials.gov